文献速递美容整形创面修复

体重指数、合并症与《柳叶刀》新肥胖定义:对整形与重建外科风险分析的启示

Body Mass Index, Comorbidities, and the New Lancet Obesity Definition: Implications for Risk Analysis in Plastic and Reconstructive Surgery.
PubMed 文献 · Plast Reconstr Surg · 2026-01-21

本研究基于TriNetX数据库957,985例整形与重建外科手术患者,分析BMI与肥胖相关合并症对30天并发症的影响。结果显示无合并症时BMI 25–29.9风险更低、30–34.9风险相近,BMI>35后风险上升;有合并症时BMI 25–39.9风险已升高。结论部分支持新肥胖定义。

要点

  • 无合并症时BMI 25–34.9手术风险不高于正常体重,减重未必改变风险。
  • BMI>35后无论有无合并症并发症风险均上升,需考虑减重或风险缓解策略。
  • 身体塑形手术中BMI≥25即显著增加风险,无论合并症状态。

核心结论

  • 研究结果部分支持《柳叶刀》新肥胖定义在整形与重建外科中的应用。
  • BMI 25–34.9无合并症者减重可能不改变手术风险,应综合评估合并症。
  • BMI≥35者建议减重或采用GLP-1受体激动剂等风险缓解策略。

研究设计与样本

  • 回顾性队列研究,查询TriNetX健康数据库。
  • 纳入957,985例接受整形与重建外科手术的患者。
  • 按BMI分类及肥胖相关合并症有无分层,行Cox回归分析30天并发症风险比。
  • 按手术复杂程度进行亚组分析。

主要发现

  • 有合并症且BMI 25–39.9者并发症风险显著高于正常体重者(HR 1.05;P<0.001)。
  • BMI≥40者并发症风险显著升高(HR 1.40;P<0.0001)。
  • 无合并症且BMI 25–29.9者风险低于正常体重者(HR 0.83;P<0.0001)。
  • 无合并症且BMI 30–34.9者风险与正常体重者相近(HR 0.99;P=0.62)。
  • 无合并症时BMI>35出现风险上升拐点;身体塑形手术中BMI≥25即显著增加风险。

关键数值与推荐

  • BMI 25–39.9且有合并症:HR 1.05(P<0.001)。
  • BMI≥40:HR 1.40(P<0.0001)。
  • 无合并症BMI 25–29.9:HR 0.83(P<0.0001)。
  • 无合并症BMI 30–34.9:HR 0.99(P=0.62)。
  • 无合并症时风险拐点位于BMI>35。

临床怎么用

  • 对BMI 25–34.9患者应全面评估肥胖相关合并症而非仅看BMI。
  • BMI≥35患者可考虑减重或GLP-1受体激动剂等风险缓解措施。
  • 身体塑形手术应更严格评估BMI≥25者的手术风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Lancet Diabetes & Endocrinology Commission on the Definition and Diagnosis of Clinical Obesity proposed a new definition of obesity that de-emphasizes body mass index (BMI) in favor of adiposity-related comorbidities. This study was performed to evaluate the relevance of this paradigm shift to plastic and reconstructive surgery (PRS) by analyzing the effects of BMI and adiposity-related comorbidities on 30-day complication rates. METHODS: The TriNetX health database was queried for patients undergoing PRS procedures. Patients were stratified by BMI categories and presence or absence of adiposity-related comorbidities. Cox regression analyses were performed to determine hazard ratios (HRs) for 30-day complications with subset analyses performed based on procedural complexity. RESULTS: Among 957,985 patients, those with a BMI between 25 and 39.9 and comorbidities (HR, 1.05; P < 0.001) or a BMI of 40 or higher (HR, 1.40; P < 0.0001) had significantly higher complication risks compared with normal-weight patients. Without comorbidities, patients with a BMI between 25 and 29.9 had a lower risk (HR, 0.83; P < 0.0001) and those with a BMI between 30 and 34.9 showed similar risk (HR, 0.99; P = 0.62) to normal-weight patients. An inflection point occurred at BMI values above 35, where the complication risk increased without comorbidities. Subset analysis revealed that BMI effects were most pronounced in body contouring procedures, with patients having a BMI of 25 or higher showing significantly increased risk, regardless of comorbidity status. CONCLUSIONS: These findings partially support the new obesity definition in the context of PRS. For patients with BMI values of 25 through 34.9 without comorbidities, weight loss may not change surgical risk. Comprehensive assessment of comorbidities should be considered for patients with a BMI between 25 and 34.9, and weight loss or other risk-mitigation strategies, such as glucagon-like peptide-1 receptor agonists, may be recommended for patients with a BMI of 35 or higher.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Tobin MJ, Mustoe AK, Ahn S, et al. Body Mass Index, Comorbidities, and the New Lancet Obesity Definition: Implications for Risk Analysis in Plastic and Reconstructive Surgery. Plast Reconstr Surg. 2026. PMID: 41557524. doi:10.1097/PRS.0000000000012830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。